Faron’s Traumakine Flops In Phase III
Executive Summary
Faron Pharmaceuticals’ stock has plummeted more than 80% on the news its lead drug failed in a Phase III trial – the company will now shift its focus to an investigational cancer therapy, but this is yet to enter the clinic.
You may also be interested in...
Coronavirus Update: Drug Shortages On Horizon, Firms Offer Medical Staff For The Fight, More Studies Start
Fears over shortages of drugs needed for ventilated patients rise, while Merck & Co, Pfizer and Lilly allow their medics to volunteer, and attention turns to beta-interferon products and NK cell therapies to fight the virus.
Faron Lifted By US Immunotherapy Trial Approval
After a major setback to its lead asset last year, Faron looks to novel immunotherapy
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.